USRE42327E1 - Medicinal compositions improving brain function and method for improving brain function - Google Patents

Medicinal compositions improving brain function and method for improving brain function Download PDF

Info

Publication number
USRE42327E1
USRE42327E1 US12/683,813 US68381304A USRE42327E US RE42327 E1 USRE42327 E1 US RE42327E1 US 68381304 A US68381304 A US 68381304A US RE42327 E USRE42327 E US RE42327E
Authority
US
United States
Prior art keywords
group
ingredient
compound
pharmaceutical composition
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US12/683,813
Other languages
English (en)
Inventor
Yasushi Nakada
Masaya Nakagawa
Satoshi Ono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of USRE42327E1 publication Critical patent/USRE42327E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to a pharmaceutical composition for improving the cerebral function which contains an alkyl ether derivative and a compound having acetylcholine esterase inhibiting activity, and to a method using an alkyl ether derivative in combination with a compound having acetylcholine esterase inhibiting activity for the purpose of. improving the cerebral function.
  • drugs for symptomatic treatment of this memory impairment for example, compounds having an acetylcholine esterase inhibiting activity such as Tacrine, Donepezil, and the like are used.
  • the anti-hypoxic activity is used for evaluating the neuroprotective activity in-vitro, and it is reported that, in the in-vivo experiments, too, compounds having a neuroprotective activity show the same effect as above [Ann. N. Y. Acad. Sci., Vol. 890, Pages 406-420, 1999]. Further, it has been reported that the anti-hypoxic activity is shown by compounds activating the in-brain acetylcholine neurons and by Tacrine (1,2,3,4-tetrahydro-9-acridinamine hydrochloride) showing an acetylcholine esterase inhibiting activity [Jpn. J. Pharmacol., Vol. 62, Pages 81-86, 1993].
  • a work for studying the in-vivo anti-hypoxic activity can be regarded as a method for evaluating the compounds having one of the neuroprotective effect and the in-brain acetylcholine neurons activating effect or both of these effects.
  • the 1,2-ethanediol derivatives or salts thereof described in JP 3-232830A and JP 4-95070A are compounds useful as a cerebral function-improving agent, and particularly (R)-1- ⁇ benzo[b]thiophen-5-yl ⁇ -2-[2-(N,N-diethylamino ⁇ ethoxy]ethanol hydrochloride (hereinafter, referred to as T-588) is a preferable compound. It has been reported that T-588 has an anti-hypoxic activity and an anti-amnestic activity, and promotes the release of in-brain acetylcholine (SOCIETY FOR NEUROSCIENCE, Abstracts, Vol. 21, Page 947, 1995).
  • T-588 exhibits a protecting effect on the neuronal death caused by amyloid-beta-protein (SOCIETY FOR NEUROSCIENCE, Abstracts, Vol. 24, Part 1, Page 228, 1998) and that T-588 exhibits an increasing effect on the action of nerve growth factor (WO96/12717).
  • SOCIETY FOR NEUROSCIENCE NEUROSCIENCE, Abstracts, Vol. 24, Part 1, Page 228, 1998)
  • T-588 exhibits an increasing effect on the action of nerve growth factor (WO96/12717).
  • WO96/12717 nerve growth factor
  • acetylcholine esterase inhibiting drugs such as Tacrine, Donepezil, Galanthamine, and the like are commercially available as cerebral function-improving drugs including Alzheimer's disease-curing drug, these drugs have problems in the point of side-reactions because some of them have a hepatic toxicity and some others have a side reaction accompanied by activation of acetylcholine neurons other than central nervous system.
  • acetylcholine esterase inhibiting drugs for example, a combination of a brain circulation metabolism improver such as Idebenone and an acetylcholine esterase inhibitor (JP 10-259126A) or a combination of a compound having a nerve growth factor-like activity (SR57746A) and an acetylcholine esterase inhibitor (WO99/25363), etc. are being attempted.
  • a brain circulation metabolism improver such as Idebenone and an acetylcholine esterase inhibitor
  • SR57746A nerve growth factor-like activity
  • WO99/25363 acetylcholine esterase inhibitor
  • R 1 represents a substituted or unsubstituted heterocyclic group
  • R 2 represents a hydrogen atom or a hydroxyl group
  • R 3 and R 4 which may be the same or different, each represents a substituted or unsubstituted alkyl, or R 3 and R 4 , taken together with the nitrogen atom to which they are linked, form a substituted or unsubstituted cyclic amino group
  • m represents an integer of 1 to 5
  • n represents an integer of 1 to 6; or a salt thereof, including T-588.
  • Halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom
  • alkyl group means a straight chain or branched chain C 1-12 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl and the like
  • lower alkyl group means a straight chain or branched chain C 1-6 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like
  • alkoxy group means a straight or branched chain C 1-12 alkyloxy group such as methoxy, ethoxy, propoxy, isoprop
  • the heterocyclic group of R 1 may be substituted with at least one residue selected from halogen atom, optionally substituted amino, lower alkyl, aryl, ar-lower alkyl, lower alkoxy, ar-lower alkoxy, aryloxy, carbamoyloxy, lower alkylthio, lower alkenyl, lower alkenyloxy, ar-lower alkylthio, ar-lower alkylsulfonyl, arylsulfonyl, lower alkylsulfonylamino, arylsulfonylamino groups, or optionally protected amino group, optionally protected hydroxyl group, nitro group, heterocyclic group, oxo group, lower alkylenedioxy group and the like.
  • halogen atom optionally substituted amino, lower alkyl, aryl, ar-lower alkyl, lower alkoxy, ar-lower alkoxy, aryloxy, carbamoyloxy, lower alkyl
  • the amino groups of R 3 and R 4 and the cyclic amino group which R 3 and R 4 form in conjunction with the nitrogen atom to which R 3 and R 4 are linked may be substituted with at least one group selected from halogen atom, optionally substituted amino group, lower alkyl group, aryl group, ar-lower alkyl group, ar-lower alkenyl group, aroyl group, ar-lower alkenoyl group, heterocyclic group and the like.
  • R 1 , R 3 , R 4 and the cyclic amino group which R 3 and R 4 form in conjunction with the nitrogen atom to which R 3 and R 4 and linked may further be substituted with at least one group selected from halogen atom, optionally protected hydroxyl group, optionally protected carboxyl group, optionally protected amino group, lower alkyl group, lower alkoxy group, lower acyl group, cycloalkyl group, ar-lower alkyl group and the like.
  • the protecting group for carboxyl group includes all the residues which can conventionally be used as a protecting group for carboxyl group, of which examples include lower alkyl groups such as methyl, ethyl, propyl, isopropyl, 1,1-dimethylpropyl, butyl, tert-butyl and the like; aryl groups such as phenyl, naphthyl and the like; ar-lower alkyl groups such as benzyl, diphenylmethyl, trityl, p-nitrobenzyl, p-methoxybenzyl, bis(p-methoxyphenyl)methyl and the like; acyl-lower alkyl groups such as acetylmethyl, benzoylmethyl, p-nitrobenzoylmethyl, p-bromobenzoylmethyl, p-methanesulfonylbenzoylmethyl and the like; oxygen-containing heterocyclic groups such as 2-tetrahydropyranyl, 2-
  • the protecting group for hydroxyl group include all the residues which can conventionally be used for protection of hydroxyl group, of which examples include acyl groups such as benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl, 2-(phenylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-a
  • the protecting group for amino group include all the residues which can conventionally be used as a protecting group for amino groups, of which examples include acyl groups such as trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, o-bromobenzyloxycarbonyl, (mono-, di- and tri-)chloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, p-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryloxycarbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, phthal
  • salts of the compounds of general formula [1] conventionally known salts formed at the position of basic group such as amino groups and the like and acidic group such as hydroxyl group, carboxyl group and the like can be referred to.
  • the salts formed at the position of basic group for example, salts formed with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like; salts formed with organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, malic acid, tartaric acid, aspartic acid and the like; and salts formed with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, naphthalenesulfonic acid and the like can be referred to.
  • salts formed at the position of acidic group for example, salts formed with an alkali metal such as sodium, potassium and the like; salts formed with an alkaline earth metal such as calcium, magnesium and the like; ammonium salts, salts formed with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-beta-phenethylamine, 1-ephenamine, N,N′-dibenzylethylenediamine and the like; etc.
  • an alkali metal such as sodium, potassium and the like
  • salts formed with an alkaline earth metal such as calcium, magnesium and the like
  • ammonium salts, salts formed with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributyl
  • alkyl ether derivatives of general formula [I] or salts thereof have isomers such as optical isomer, geometrical isomer, tautomer, etc.
  • the present invention involves all those isomers, and further involves hydrates, solvates and all the crystalline forms.
  • alkyl ether derivative or salt thereof used as the ingredient (A) compounds represented by general formula [1] in which the substituents are selected from the following combinations are preferable.
  • R 1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atoms, alkyl groups and phenyl group
  • R 2 is a hydroxyl group
  • R 3 is an alkyl group
  • R 4 is an alkyl group which may be substituted with an alkoxy-substituted phenyl group or R 3 and R 4 , taken in conjunction with a nitrogen atom to which R 3 and R 4 are linked, form a pyrrolidine ring, piperidine ring, piperazine ring or a morpholine ring
  • m is 1
  • n is 2.
  • R 1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atom, alkyl group optionally substituted with hydroxyl group, alkoxy group, carboxyl group, aminocarbonyl group, hydroxyl group, alkylthio group, phenyl group and pyridyl group;
  • R 2 is a hydrogen atom;
  • R 3 is an alkyl group which may be substituted with a group selected from phenyl group optionally substituted with halogen atom, alkoxy group or nitro group, optionally protected hydroxyl group, alkylamino group and alkynyl group;
  • R 4 is an alkyl group which may be substituted with a phenyl group;
  • a specific example of such a compound is 2-[[3-(2-benzo[b]thiophen-5-ylethoxy)propyl](methyl)amino]-1-ethanol.
  • R 1 is a benzothienyl or benzofuranyl group which may be substituted with a group selected from halogen atom, alkyl group and phenyl group
  • R 2 is a hydrogen atom
  • R 3 or R 4 is an alkyl group which may be substituted with hydroxyl group, optionally protected amino group and alkylamino group, or R 3 and R 4 represent an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring which is formed by R 3 and R 4 together with the nitrogen atom to which R 3 and R 4 are linked
  • m is 1
  • n is 2 to 3.
  • alkyl ether derivatives of general formula [1] or salts thereof can be produced according to the method described in JP 3-47158A, JP 3-232830A, JP 4-95070A, WO99/31056, WO00/76957, PCT/JP02/10827, etc.
  • ingredient (B) As the compound having an acetylcholine esterase inhibiting activity used in this invention as ingredient (B), for example, the following can be referred to:
  • a pharmaceutical preparation such as tablet, capsule, powder, granule, fine granule, pill, suspension, emulsion, solution, syrup, injection, eye drop and the like can be formed in the usual manner by appropriately using pharmaceutically acceptable assistants such as excipient, carrier, diluent, stabilizer and the like.
  • the pharmaceutical preparation thus formed can be administered orally or non-orally.
  • the proportions of the ingredients (A) and (B) may be selected appropriately, the amount of ingredient (B) is 0.0005-1 part by weight per 1 part by weight of ingredient (A).
  • the amounts of ingredients (A) and (B) vary depending on the combination thereof, for example, the amount of ingredient (B) (the compound having an acetylcholine esterase inhibitory activity) may be an amount at which a reaction of the peripheral nervous symptom (predominantly, the reaction caused by the parasympathetic nervous system such as diarrhoea, lacrimmation, salivation, etc.) does not appear significantly.
  • the amount of ingredient (B) may be an amount at which a reaction of the peripheral nervous symptom (predominantly, the reaction caused by the parasympathetic nervous system such as diarrhoea, lacrimmation, salivation, etc.) does not appear significantly.
  • the amount is about 0.05 mg to 10 mg per day in the case of Donepezil, about 1 mg to 120 mg per day in the case of Zanapezil, about 5 mg to 200 mg per day in the case of Tacrine, about 10 mg to 300 mg per day in the case of Ipidacrine, and about 0.5 mg to 20 mg per day in the case of Rivastigmine.
  • ingredient (A) varies depending on the kind of ingredient (B), namely the compound having an acetylcholine esterase inhibitory activity, it is 0.01 to 500 mg per day.
  • Test compounds A1, A2, A3, B1 and B2 were put to use after dissolution in distilled water.
  • Test compounds C1 and C2 were put to use after suspending them in 0.5% solution of methylcellulose.
  • test was carried out according to the method described in Japanese Journal of Pharmacology, Vol. 62, Page 81, 1993.
  • mice To one group (6-10 animals) of ddY male mice having an age of 4-5 weeks was orally administered a test compound dissolved in distilled water or suspended in 0.5% methyl cellulose solution. Thirty minutes after the administration, the mice were introduced into a glass container at a volume of 300 mL, and a gaseous mixture composed of 4% of oxygen and 96% of nitrogen was passed though the glass container at a flow rate of 5 L/minute. The period of time from the start of passing the gaseous mixture to the death of the mice was measured. To the control group, distilled water was administered orally.
  • the anti-hypoxic activity of each test compound was calculated according to the following formula: (Survival time of mouse in the test compound ⁇ administered group/Survival time of mouse in the control group) ⁇ 100% The results are shown in Tables 1-3.
  • Anti-hypoxic activity can synergistically be improved by combining the alkyl ether derivative of general formula [1] or a salt thereof with a compound having an acetylcholine esterase inhibitory activity. Accordingly, the combination of this invention is useful as a method for improving the cerebral function.
  • a pharmaceutical composition containing the compound according to the combination of this invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequela of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
US12/683,813 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function Expired - Lifetime USRE42327E1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002173483 2002-06-14
JP2002-173483 2002-06-14
PCT/JP2003/004292 WO2003105830A1 (ja) 2002-06-14 2003-04-03 脳機能を改善する医薬組成物および脳機能を改善するための方法

Publications (1)

Publication Number Publication Date
USRE42327E1 true USRE42327E1 (en) 2011-05-03

Family

ID=29727916

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/683,813 Expired - Lifetime USRE42327E1 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function
US10/516,320 Ceased US7342043B2 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function
US11/957,832 Expired - Lifetime US7834053B2 (en) 2002-06-14 2007-12-17 Medicinal compositions improving brain function and method for improving brain function

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/516,320 Ceased US7342043B2 (en) 2002-06-14 2003-04-03 Medicinal compositions improving brain function and method for improving brain function
US11/957,832 Expired - Lifetime US7834053B2 (en) 2002-06-14 2007-12-17 Medicinal compositions improving brain function and method for improving brain function

Country Status (23)

Country Link
US (3) USRE42327E1 (pt)
EP (2) EP1514542B1 (pt)
JP (1) JP4675103B2 (pt)
KR (1) KR100935615B1 (pt)
CN (1) CN100375619C (pt)
AT (1) ATE546140T1 (pt)
AU (1) AU2003236364C1 (pt)
BR (1) BRPI0311780B8 (pt)
CA (1) CA2488120C (pt)
CY (2) CY1112958T1 (pt)
DK (2) DK1514542T3 (pt)
ES (2) ES2379948T3 (pt)
HU (1) HUE041842T2 (pt)
IL (1) IL165589A (pt)
MX (1) MXPA04012534A (pt)
NO (1) NO333504B1 (pt)
NZ (1) NZ537090A (pt)
PL (1) PL217394B1 (pt)
PT (2) PT1514542E (pt)
SI (2) SI2389937T1 (pt)
TR (1) TR201816386T4 (pt)
WO (1) WO2003105830A1 (pt)
ZA (1) ZA200409901B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43676E1 (en) 2001-10-19 2012-09-18 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379948T3 (es) 2002-06-14 2012-05-07 Toyama Chemical Co., Ltd. Composición medicinal que comprende Tacrine o Donepezil para mejorar la función cerebral
ES2391273T3 (es) * 2003-04-17 2012-11-23 Toyama Chemical Co., Ltd. Agente preventivo/curativo para enfermedades del nervio retiniano que contiene derivados de éter alquílico o sus sales
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP2258357A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
JP5695293B2 (ja) * 2006-04-26 2015-04-01 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
CA2659835A1 (en) * 2006-08-04 2008-02-07 Toyama Chemical Co., Ltd. Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
MX2010012787A (es) * 2008-05-28 2011-02-24 Toyama Chemical Co Ltd Nuevo derivado de oxido de benzotiofeno y sal del mismo.
ES2694202T3 (es) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Idebenona deuterada
MY179290A (en) * 2014-01-31 2020-11-03 Fujifilm Toyama Chemical Co Ltd Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
CA3067455C (en) * 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
SG11201911520UA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating tauopathy
CN116473962A (zh) 2017-06-02 2023-07-25 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
AU2018301222A1 (en) * 2017-07-08 2020-01-30 The General Hospital Corporation Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease
WO2019088083A1 (ja) 2017-10-30 2019-05-09 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
CN110464834B (zh) * 2019-09-04 2022-12-02 北京豪思生物科技股份有限公司 铜蓝蛋白联合多奈哌齐的应用
KR20220040291A (ko) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
KR20220040294A (ko) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225158A (ja) 1985-03-05 1986-10-06 プロテ−ラ・アクチエンゲゼルシャフト フエニルカルバメート類
JPS62215527A (ja) 1986-01-15 1987-09-22 ボニ−、デイビス アルツハイマー病治療薬
JPS6479151A (en) 1987-06-22 1989-03-24 Eisai Co Ltd Cyclic amine derivative
JPH0210827A (ja) 1988-06-29 1990-01-16 Matsushita Electron Corp 半導体装置の製造方法
EP0383281A1 (en) 1989-02-14 1990-08-22 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JPH0347158A (ja) 1989-04-26 1991-02-28 Toyama Chem Co Ltd １，２−エタンジオール誘導体またはその塩
JPH03232830A (ja) 1990-02-05 1991-10-16 Toyama Chem Co Ltd １，２―エタンジオール誘導体およびその塩
US5081117A (en) * 1989-09-28 1992-01-14 Hoechst-Roussel Pharmaceuticals Incorporated 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof
JPH0495070A (ja) 1990-08-09 1992-03-27 Toyama Chem Co Ltd １，２―エタンジオール誘導体およびその塩
WO1992018493A1 (de) 1991-04-11 1992-10-29 Dr. Willmar Schwabe Gmbh & Co. Benzopyranone, verfahren zu ihrer herstellung und verwendung
US5177082A (en) 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
CA2081808A1 (en) 1991-11-04 1993-05-05 Maarten De Jonge Combination of calcium antagonists with cholinesterase inhibitors
JPH05140149A (ja) 1990-11-22 1993-06-08 Takeda Chem Ind Ltd 縮合複素環誘導体
JPH05279355A (ja) 1990-10-19 1993-10-26 Ss Pharmaceut Co Ltd キノリン誘導体及びこれを含有する医薬
WO1996012717A1 (fr) 1994-10-25 1996-05-02 Toyama Chemical Co., Ltd. Potentialisateur de l'activite du facteur de croissance nerveuse contenant un derive de 1,2-ethanediol ou un sel de celui-ci
WO1996026196A2 (en) 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines and piperazines as muscarinic antagonists
WO1997030703A1 (fr) 1996-02-20 1997-08-28 Toyama Chemical Co., Ltd. Agent ameliorant les fonctions cerebrales contenant des derives de 1,2-ethanediol ou des sels de celui-ci
WO1998001425A1 (en) 1996-07-10 1998-01-15 Schering Corporation 1,4-di-sustituted piperidines as muscarinic antagonists
WO1998005292A2 (en) 1996-08-08 1998-02-12 Schering Corporation Piperidine and piperazine derivatives and their use as muscarinic antagonists
WO1998006697A1 (en) 1996-08-15 1998-02-19 Schering Corporation Ether muscarinic antagonists
JPH10259126A (ja) 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
WO1999025363A1 (fr) 1997-11-14 1999-05-27 Sanofi-Synthelabo Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer
WO1999031056A1 (fr) 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant
WO2000076957A1 (fr) 1999-06-11 2000-12-21 Toyama Chemical Co., Ltd. Derives de n-alkoxyalkyl, n-dialkylamine ou leurs sels et remedes contre les maladies a degenerescence nerveuse, qui les contiennent
WO2003035647A1 (fr) 2001-10-19 2003-05-01 Toyama Chemical Co., Ltd. Derives ou sels d'ether d'alkyle
US20050250843A1 (en) 2002-06-14 2005-11-10 Yasushi Nakada Medicinal compositions improving brain function and method for improving brain function
US20060205709A1 (en) 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US20090093453A1 (en) 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US20090209512A1 (en) 2006-04-26 2009-08-20 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP2925363B2 (ja) 1991-07-09 1999-07-28 キヤノン株式会社 画像処理方法及び装置
JP3232830B2 (ja) 1993-11-30 2001-11-26 三菱電機株式会社 フレキシブルディスク装置のキャリッジ機構
US20030092737A1 (en) 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225158A (ja) 1985-03-05 1986-10-06 プロテ−ラ・アクチエンゲゼルシャフト フエニルカルバメート類
US5177082A (en) 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
JPS62215527A (ja) 1986-01-15 1987-09-22 ボニ−、デイビス アルツハイマー病治療薬
JPS6479151A (en) 1987-06-22 1989-03-24 Eisai Co Ltd Cyclic amine derivative
JPH0210827A (ja) 1988-06-29 1990-01-16 Matsushita Electron Corp 半導体装置の製造方法
EP0383281A1 (en) 1989-02-14 1990-08-22 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JPH0347158A (ja) 1989-04-26 1991-02-28 Toyama Chem Co Ltd １，２−エタンジオール誘導体またはその塩
US5081117A (en) * 1989-09-28 1992-01-14 Hoechst-Roussel Pharmaceuticals Incorporated 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof
JPH03232830A (ja) 1990-02-05 1991-10-16 Toyama Chem Co Ltd １，２―エタンジオール誘導体およびその塩
JPH0495070A (ja) 1990-08-09 1992-03-27 Toyama Chem Co Ltd １，２―エタンジオール誘導体およびその塩
JPH05279355A (ja) 1990-10-19 1993-10-26 Ss Pharmaceut Co Ltd キノリン誘導体及びこれを含有する医薬
JPH05140149A (ja) 1990-11-22 1993-06-08 Takeda Chem Ind Ltd 縮合複素環誘導体
WO1992018493A1 (de) 1991-04-11 1992-10-29 Dr. Willmar Schwabe Gmbh & Co. Benzopyranone, verfahren zu ihrer herstellung und verwendung
CA2081808A1 (en) 1991-11-04 1993-05-05 Maarten De Jonge Combination of calcium antagonists with cholinesterase inhibitors
JPH05221877A (ja) 1991-11-04 1993-08-31 Troponwerke Gmbh & Co Kg カルシウム拮抗剤とコリンエステラーゼ阻害剤の組み合わせ
WO1996012717A1 (fr) 1994-10-25 1996-05-02 Toyama Chemical Co., Ltd. Potentialisateur de l'activite du facteur de croissance nerveuse contenant un derive de 1,2-ethanediol ou un sel de celui-ci
WO1996026196A2 (en) 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines and piperazines as muscarinic antagonists
JPH11501014A (ja) 1995-02-23 1999-01-26 シェーリング コーポレイション ムスカリン様アンタゴニストとしてのベンジルピペリジンおよびピペラジン
WO1997030703A1 (fr) 1996-02-20 1997-08-28 Toyama Chemical Co., Ltd. Agent ameliorant les fonctions cerebrales contenant des derives de 1,2-ethanediol ou des sels de celui-ci
WO1998001425A1 (en) 1996-07-10 1998-01-15 Schering Corporation 1,4-di-sustituted piperidines as muscarinic antagonists
JPH11514671A (ja) 1996-07-10 1999-12-14 シェーリング コーポレイション ムスカリン様アンタゴニストとしての１，４―ジ―置換ピペリジン
WO1998005292A2 (en) 1996-08-08 1998-02-12 Schering Corporation Piperidine and piperazine derivatives and their use as muscarinic antagonists
JP2000501117A (ja) 1996-08-08 2000-02-02 シェーリング コーポレイション ムスカリン様アンタゴニスト
JP2000500786A (ja) 1996-08-15 2000-01-25 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
WO1998006697A1 (en) 1996-08-15 1998-02-19 Schering Corporation Ether muscarinic antagonists
JPH10259126A (ja) 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
JP2001523642A (ja) 1997-11-14 2001-11-27 サノフィ−サンテラボ アルツハイマー型痴呆のような老人性痴呆を治療するための活性成分、特にテトラヒドロピリジン類とアセチルコリンエステラーゼ阻害剤との組み合わせ
WO1999025363A1 (fr) 1997-11-14 1999-05-27 Sanofi-Synthelabo Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer
WO1999031056A1 (fr) 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant
WO2000076957A1 (fr) 1999-06-11 2000-12-21 Toyama Chemical Co., Ltd. Derives de n-alkoxyalkyl, n-dialkylamine ou leurs sels et remedes contre les maladies a degenerescence nerveuse, qui les contiennent
EP1186594A1 (en) 1999-06-11 2002-03-13 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
US6797726B1 (en) * 1999-06-11 2004-09-28 Toyama Chemical Co., Ltd. N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
WO2003035647A1 (fr) 2001-10-19 2003-05-01 Toyama Chemical Co., Ltd. Derives ou sels d'ether d'alkyle
US20090111992A1 (en) 2001-10-19 2009-04-30 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
US20050250843A1 (en) 2002-06-14 2005-11-10 Yasushi Nakada Medicinal compositions improving brain function and method for improving brain function
US20080103126A1 (en) 2002-06-14 2008-05-01 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brian function
US20060205709A1 (en) 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US20090093453A1 (en) 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US20090209512A1 (en) 2006-04-26 2009-08-20 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Ikeda, Ken et al. "T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease", Brain Research, vol. 858, No. 1, pp. 84-91 2000.
Mealy et al., Drugs of the future, 2002, 27(9): 879-915. *
Ono, S. et al. "Effects of T-588, a novel cognitive enhancer, on acetylcholine and monoamine releases and second-messenger systems in rats", Society for Neuroscience, vol. 21, p. 947, #377.2 1995.
Ono, S. et al. "T-588, a novel cognition enhancer, protects cortical cell cultures against both beta-amyloid-and 4-hydroxy-2-nonenal-induced apoptosis", Society for Neuroscience, vol. 24, part 1, p. 228, #91.7 1998.
Ono, Satoshi et al. "Protective Effect of R(-)-1-(Benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol Hydrochloride (T-588), a Novel Celebral Activator, against Experimental Cerebral Anoxia", Japan, J. Pharmacol., vol. 62, No. 1, pp. 81-86 1993.
Ono, Satoshi et al. "Protective Effect of R(−)-1-(Benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol Hydrochloride (T-588), a Novel Celebral Activator, against Experimental Cerebral Anoxia", Japan, J. Pharmacol., vol. 62, No. 1, pp. 81-86 1993.
Palmer, Gene C. et al. "The Low-Affinity, Use-Dependent NMDA Receptor Antagonist AR-R 15896AR", Annals New York Academy of Sciences, vol. 890, pp. 406-420 1999.
Shimada et al., 1997, CAS:127:362624. *
U.S. Appl. No. 10/553,120, filed Oct. 14, 2005, Kimura, et al.
U.S. Appl. No. 11/416,321, filed May 3, 2006, Saitoh et al.
U.S. Appl. No. 11/957,832, filed Dec. 17, 2007, Nakada, et al.
U.S. Appl. No. 12/253,379, filed Oct. 17, 2008, Saitoh, et al.
U.S. Appl. No. 12/298,656, filed Oct. 27, 2008, Iwakami, et al.
U.S. Appl. No. 12/370,736, filed Feb. 13, 2009, Iwakami, et al.
U.S. Appl. No. 12/542,074, filed Aug. 17, 2009, Kimura, et al.
U.S. Appl. No. 12/683,813, filed Jan. 7, 2010, Nakada, et al.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43676E1 (en) 2001-10-19 2012-09-18 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof

Also Published As

Publication number Publication date
ATE546140T1 (de) 2012-03-15
JPWO2003105830A1 (ja) 2005-10-13
EP1514542A1 (en) 2005-03-16
BRPI0311780B8 (pt) 2021-05-25
NO333504B1 (no) 2013-06-24
KR20050010877A (ko) 2005-01-28
EP2389937B1 (en) 2018-08-15
CY1120591T1 (el) 2019-12-11
CN100375619C (zh) 2008-03-19
CY1112958T1 (el) 2016-04-13
BR0311780A (pt) 2005-03-15
CA2488120A1 (en) 2003-12-24
AU2003236364B2 (en) 2008-08-21
US20050250843A1 (en) 2005-11-10
PL372934A1 (en) 2005-08-08
KR100935615B1 (ko) 2010-01-07
DK1514542T3 (da) 2012-04-10
ZA200409901B (en) 2006-07-26
ES2379948T3 (es) 2012-05-07
IL165589A0 (en) 2006-01-15
DK2389937T3 (en) 2018-11-12
JP4675103B2 (ja) 2011-04-20
WO2003105830A1 (ja) 2003-12-24
HUE041842T2 (hu) 2019-05-28
PL217394B1 (pl) 2014-07-31
BRPI0311780B1 (pt) 2017-09-26
PT2389937T (pt) 2018-10-26
SI2389937T1 (sl) 2018-10-30
NO20045158L (no) 2005-03-10
AU2003236364A1 (en) 2003-12-31
CN1662232A (zh) 2005-08-31
US7342043B2 (en) 2008-03-11
ES2685923T3 (es) 2018-10-15
IL165589A (en) 2012-04-30
US7834053B2 (en) 2010-11-16
PT1514542E (pt) 2012-03-27
EP1514542A4 (en) 2009-06-03
EP1514542B1 (en) 2012-02-22
MXPA04012534A (es) 2005-04-19
EP2389937A1 (en) 2011-11-30
SI1514542T1 (sl) 2012-06-29
TR201816386T4 (tr) 2018-11-21
CA2488120C (en) 2012-04-17
AU2003236364C1 (en) 2009-12-24
US20080103126A1 (en) 2008-05-01
NZ537090A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
US7834053B2 (en) Medicinal compositions improving brain function and method for improving brain function
US5484808A (en) Methods of inhibiting cell-cell adhesion
EP3100725A1 (en) Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
ZA200402806B (en) Alkyl ether derivatives or their salts
KR101233711B1 (ko) 항염증제로서 유용한 알파-아미노아미드 유도체
CZ285633B6 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
JP2001527551A (ja) Ｍｔｐインヒビターと脂溶性ビタミンの組合せおよび該組合せを用いる血清脂質レベルの降下法
JPH0623105B2 (ja) てんかんの発作の治療用製薬組成物
EE200100193A (et) 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
TH18631A (th) วิธีการยับยั้งธรอมบิน
MXPA97005215A (en) Use of 2-phenyl-3-aroylbenzotiophenes to inhibit effects of growth hormone
TH14758B (th) วิธีการยับยั้งธรอมบิน

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12